Get the Stockscreener App
122.81
1.11%
1.4426
State Street Spdr S P Biotech Etf stock is traded at $122.81, with a volume of 5.74M.
It is up +1.11% in the last 24 hours and up +13.22% over the past month.
See More
Previous Close:
$121.37
Open:
$121.55
24h Volume:
5.74M
Relative Volume:
0.56
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+7.17%
1M Performance:
+13.22%
6M Performance:
+55.26%
1Y Performance:
+24.14%
1-Day Range:
$120.95
$122.92
1-Week Range:
$113.57
$122.92
52-Week Range:
$66.66
$122.92
State Street Spdr S P Biotech Etf Stock (XBI) Company Profile
Name
State Street Spdr S P Biotech Etf
Sector
Industry
Phone
-
Address
-
Compare XBI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBI
State Street Spdr S P Biotech Etf
|
122.85 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
334.93 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
680.59 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
683.90 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
258.23 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
614.75 | 124.43B | 0 | 0 | 0 | 0.00 |
State Street Spdr S P Biotech Etf Stock (XBI) Latest News
Apple, Taiwan Semiconductor Manufacturing And More On CNBC's 'Final Trades' - Benzinga
Best-Performing ETFs of Last Week: Healthcare Rules - sharewise.com
Why biotech and drug stocks are on the mend even though the rest of the market is hurting - MSN
ETFs Investing in Janux Therapeutics, Inc. Stocks - TradingView
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double - Markets Financial Content
S&P 500: Health Care Stocks Come Alive — Nudging Tech Aside For Now - Investor's Business Daily
Biotech ETF (XBI) Hits New 52-Week High - MSN
Biotech Stock Gets Booted in Latest Fund Update - The Motley Fool
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? - sharewise.com
(11/19/25) PFE: The Winner in the Metsera Bidding War - moneyshow.com
Why biotech and drug stocks are rallying even though the rest of the market is hurting - MarketWatch
M&A Injects Life Into Biotech Trade - TheStreet Pro
XBI: Biotech Funding Condition Recovery Could Be Overdue (NYSEARCA:XBI) - Seeking Alpha
XBI: An Equal Weight ETF On Biotech That Amplifies Its Speculative Component - Seeking Alpha
Breakthrough bets on life sciences rebound with $430m fundraise - Private Equity Real Estate | PERE
This Biotech Stock Soared 100%. Merck Is Buying It. - Barron's
META_TITLE_SECTORS - Yahoo Finance
Two Biotech Stocks to Watch as Sector Bounces Back - TheStreet Pro
Should You Invest in the State Street SPDR S&P Semiconductor ETF (XSD)? - Yahoo Finance
Should You Invest in the State Street SPDR S&P Oil & Gas Exploration & Production ETF (XOP)? - Nasdaq
Is State Street SPDR S&P Retail ETF (XRT) a Strong ETF Right Now? - sharewise.com
Is State Street SPDR S&P Bank ETF (KBE) a Strong ETF Right Now? - Yahoo Finance
Should You Invest in the State Street SPDR S&P Retail ETF (XRT)? - Nasdaq
Is the Drought in Life-Sciences IPOs Over? Two Startups Will Test Demand - The Wall Street Journal
Experiments, Mergers, and Interest Rate Cuts: The Biotechnology Sector Ushers in a New Cycle - NAI500
SPDR S&P Biotech ETF declares quarterly distribution of $0.0267 - MSN
SPDR S&P Biotech ETF Options Spot-On: On November 3rd, 78,510 Contracts Were Traded, With 811.5K Open Interest - 富途牛牛
SPDR S&P Biotech ETF (XBI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over? - Benzinga
Biopharmaceutical stocks performed strongly against the market trend, bolstered by industry mergers and acquisitions as well as favorable policy developments. - 富途牛牛
It's a high-risk trade, but this biotech down 80% this year could be a buy - CNBC
Top 6 ETFs To Watch As Wall Street's Strongest Six Months Begin - Benzinga
Biotech ETFs Hovering Around a 52-Week: Here's Why - TradingView
Why Is Intellia Therapeutics Stock Sinking Monday?Intellia Therapeutics (NASDAQ:NTLA) - Benzinga
StockWatch: Top 3 Biotech ETFs Finally Bounce Back with the Market - Genetic Engineering and Biotechnology News
Have Biotech Stocks Returned To Health After Years Of Sickness? - Investor's Business Daily
Analyst Says He’s Buying This Biotech ETF, Predicts ‘Multi-Year’ Breakout - Insider Monkey
Guarantor: JPMorgan Chase & Co. - StreetInsider
Biotech Is Finally Rallying. Why Mizuho’s Jared Holz Is Optimistic This Time. - Barron's
XBI, CRSP, INSM, IONS: Large Inflows Detected at ETF - Nasdaq
The Technical Signals Behind (XBI) That Institutions Follow - news.stocktradersdaily.com
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures - Benzinga
(XBI) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
(XBI) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Discipline and Rules-Based Execution in XBI Response - news.stocktradersdaily.com
XPH: Small-Cap Pharma Turns Higher, At Long Last (NYSEARCA:XPH) - Seeking Alpha
Precision Trading with Spdr Biotech Etf (XBI) Risk Zones - news.stocktradersdaily.com
String of acquisitions fuels biotech optimism - Sherwood News
Should You Invest in the SPDR S&P Biotech ETF (XBI)? - Yahoo Finance
Truist Financial Corp Sells 5,213 Shares of SPDR S&P Biotech ETF $XBI - Defense World
Vontobel Holding Ltd. Sells 7,846 Shares of SPDR S&P Biotech ETF $XBI - Defense World
State Street Spdr S P Biotech Etf Stock (XBI) Financials Data
There is no financial data for State Street Spdr S P Biotech Etf (XBI). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):